Clinical Research Study on Methamphetamine Use with Positive Outcomes
Oceanside Treatment Center Nassau, Bahamas
A Prospective Longitudinal Observational Study on Clinical Ibogaine Treatment for Methamphetamine Use Disorder
1. Introduction
Methamphetamine use disorder is a significant and escalating public health challenge due to the drug’s high potential for addiction and neurotoxicity. In response to the need for more effective treatment strategies, this study was conducted at Oceanside Treatment Center in Nassau, Bahamas, to evaluate the outcomes of Clinical Ibogaine Treatment in individuals with methamphetamine dependence. The primary goal was to assess abstinence at 3, 6, and 12 months post-treatment among clients who completed the full protocol and engaged in structured aftercare.
2. Study Design
Study Type: Prospective Longitudinal Observational Study
Location: Oceanside Treatment Center, Nassau, Bahamas
Study Duration: 12 months (March 24, 2023 – March 22, 2024)
Sample Size: 24 clients
Inclusion Criteria:
– Diagnosed with methamphetamine use disorder
– Daily use of methamphetamine between 0.5g and 2g
– Duration of use from 1 to 6 years
– Adults aged 18 and over
3. Participant Demographics
Total Participants: 24
Gender Breakdown:
– Male: 14 (58.3%)
– Female: 6 (41.7%)
Use History:
– Daily methamphetamine use ranged from 0.5 grams to 2 grams
– Duration of abuse ranged from 1 to 6 years
4. Treatment Protocol
Participants completed an 8-day inpatient treatment protocol consisting of the following components:
Days 1-5 (Pre-treatment Transition Phase):
– Medical assessment and stabilization
– Nutritional support and detox preparation
– Psychosocial counseling and integration
Day 6 (Ibogaine Administration):
– Clinical Ibogaine dose administered under full-time medical supervision
Days 7-8 (Post-treatment Monitoring):
– Observation, rest, and discharge planning
5. Aftercare Program
Following treatment, all clients participated in a structured aftercare counseling program, designed to reinforce the therapeutic effects of Ibogaine and support long-term abstinence.
Months 1-6: Two counseling sessions per week
Months 7-12: One counseling session per week
Participation Rate: 60% of participants engaged consistently in aftercare throughout the 12-month follow-up period
6. Outcome Measures
Primary Outcome: Abstinence from methamphetamine use at 3, 6, and 12 months post-treatment.
Time Point | Clients Abstinent | Percentage (n = 24)
————– |——————-|———————
3 Months | 22 | 92%
6 Months | 20 | 83%
12 Months | 18 | 75%
Abstinence was determined through self-reporting, clinical observation, and follow-up assessments conducted during aftercare.
7. Observations
– Participants demonstrated a strong initial response to Ibogaine therapy, with a 92% abstinence rate at 3 months.
– Sustained abstinence at 6 months (83%) and 12 months (75%) indicates promising long-term efficacy.
– Continued engagement in counseling and support services appeared to positively influence recovery outcomes.
– The structured 8-day program, combined with consistent follow-up care, provided a comprehensive and effective framework for recovery from methamphetamine use disorder.
8. Conclusion
This prospective observational study provides evidence that Clinical Ibogaine Treatment, when delivered in a medically supervised and structured environment, can result in high rates of abstinence from methamphetamine use. The integration of aftercare support played a critical role in sustaining recovery, with strong outcomes observed at 3, 6, and 12 months post-treatment.
• 3 Months: 22 of 24 clients abstinent (92%)
• 6 Months: 20 of 24 clients abstinent (83%)
• 12 Months: 18 of 24 clients abstinent (75%
Contact Details
Name: Oceanside Treatment Center
Phone: 1-800-386-0038
Email: bahamasoceanside@gmail.com OR Intakeoceanside@gmail.com
Website: www.oceansideibogaine.com